scholarly journals TCT-642 Stent thrombosis rates in abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients undergoing percutaneous coronary intervention: 3 Year Follow-Up from the COMPARE II trial

2014 ◽  
Vol 64 (11) ◽  
pp. B187
Author(s):  
Sjoerd H. Hofma ◽  
Georgios J. Vlachojannis ◽  
Pieter C. Smits ◽  
Mario Togni ◽  
Nicolas Vazquez ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Stent Thrombosis ◽  
Biodegradable Polymer ◽  
Coronary Intervention ◽  
Durable Polymer ◽  
Percutaneous Coronary

scholarly journals Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

2016 ◽  
Vol 43 (2) ◽  
pp. 126-130 ◽  
Author(s):  
Ehsan Parsa ◽  
Sepideh Saroukhani ◽  
Fereshteh Majlessi ◽  
Hamidreza Poorhosseini ◽  
Masoumeh Lofti-Tokaldany ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Biodegradable Polymer ◽  
Coronary Intervention ◽  
Stent Group ◽  
Cardiac Events ◽  
Durable Polymer ◽  
Adverse Cardiac Events ◽  
Percutaneous Coronary

We compared outcomes of percutaneous coronary intervention patients who received biodegradable-polymer biolimus-eluting stents with those who received durable-polymer everolimus-eluting stents. At Tehran Heart Center, we performed a retrospective analysis of the data from January 2007 through December 2011 on 3,270 consecutive patients with coronary artery disease who underwent percutaneous coronary intervention with the biodegradable-polymer biolimus-eluting stent or the durable-polymer everolimus-eluting stent. We excluded patients with histories of coronary artery bypass grafting or percutaneous coronary intervention, acute ST-segment-elevation myocardial infarction, or the implantation of 2 different stent types. Patients were monitored for 12 months. The primary endpoint was a major adverse cardiac event, defined as a composite of death, nonfatal myocardial infarction, and target-vessel and target-lesion revascularization. Durable-polymer everolimus-eluting stents were implanted in 2,648 (81%) and biodegradable-polymer biolimus-eluting stents in 622 (19%) of the study population. There was no significant difference between the 2 groups (2.7% vs 2.7%; P=0.984) in the incidence of major adverse cardiac events. The cumulative adjusted probability of major adverse cardiac events in the biodegradable-polymer biolimus-eluting stent group did not differ from that of such events in the durable-polymer everolimus-eluting stent group (hazard ratio=0.768; 95% confidence interval, 0.421–1.44; P=0.388). We conclude that in our patients the biodegradable-polymer biolimus-eluting stent was as effective and safe, during the 12-month follow-up period, as was the durable-polymer everolimus-eluting stent.

RETROSPECTIVE STUDY OF CLINICAL & EPIDEMIOLOGICAL PARAMETERS OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH THEIR FOLLOW-UP

2021 ◽  
pp. 38-40
Author(s):  
Sunil Washimkar ◽  
Rohan Parikh ◽  
Atul Singh Rajput ◽  
Pradeep Deshmukh
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Stent Thrombosis ◽  
Real World ◽  
Second Generation ◽  
Coronary Intervention ◽  
Real World Data ◽  
World Data ◽  
Percutaneous Coronary ◽  
Epidemiological Parameters

Aim:To study clinical and epidemiological parameters of patients undergoing percutaneous coronary intervention (PCI) and to follow them up for understanding outcomes of procedure. Materials & methods:This is retrospective data analysis of 862 patients who underwent PCI from January 2016 to November 2017 Results: Out of 862 patients, 611 (70.88%) were male & 251 (29.12%) were female, with mean age being 55. 243 (28.19%) were diabetic, 470 (54.52%) were hypertensive, 158 (18.32%) patients were tobacco chewer, 215 (24.92%) were smokers & 111 (12.87%) were alcoholic. 636 (73.78%) patients had STEMI, 153 (17.74%) had NSTE-ACS, 61 (7.07%) had CSA.578 (67.05%) were SVD, 262 (30.39%) were DVD & 19 (2.20%) were TVD. Out of SVD, 350 (60.55%) patients had LAD involvement and among DVD patients, LAD & RCA were most commonly involved in 107 (40.83%) patients. On follow-up of mean 604.42 days (minimum 236 days, maximum 909 days), 2 (0.23%) episodes of subacute stent thrombosis occurred & 11 (1.27%) patients had ISR but no mortality was reported. Summary: The study shows affection of young population predominately and gender inequality suggesting primarily male disease. PCI is often sought in ACS and CSAis predominately treated medically. Thrombolysis still remains the rst treatment received by STEMI patients. SVD is the most common angiographic diagnosis with LAD predominately affected vessel. This real world-data on clopidogrel with aspirin as dual antiplatelet therapy and second generation stent shows negligible event of stent thrombosis & ISR. Limitation: Due to non-invasive follow-up, exact amount of stent restenosis can not be calculated. Impact on daily practice: This real world-data on clopidogrel with aspirin as dual anti-platelet therapy and second generation stent shows negligible event of stent thrombosis & ISR. This can help reduce cost burden on society and help better distribution of health budget.

P6241Two-year clinical outcomes of biodegradable polymer versus durable polymer drug-eluting stent implantation in hemodialysis patients after percutaneous coronary intervention

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
S Okuno ◽  
T Ishihara ◽  
O Iida ◽  
M Asai ◽  
M Masuda ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Clinical Outcomes ◽  
Outcome Measures ◽  
Biodegradable Polymer ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Safety And Efficacy ◽  
Durable Polymer ◽  
Percutaneous Coronary ◽  
Drug Eluting

Abstract Background Biodegradable polymer drug-eluting stent (BP-DES) has been developed to improve clinical outcomes after percutaneous coronary intervention (PCI) for patients presenting coronary artery disease (CAD). Although BP-DES showed non-inferior safety and efficacy to durable polymer DES (DP-DES) in several randomized clinical trials, hemodialysis (HD) patients, who have been well known as high risk population for adverse events, were excluded in the most of trials. Therefore, there are limited data comparing the clinical outcomes between BP-DES and DP-DES in HD patients with CAD after PCI. Purpose The purpose of this study was to investigate clinical outcomes in HD patients after BP-DES implantation compared with those after DP-DES implantation. Methods We retrospectively analyzed 234 HD patients (male 74%, mean age 71±10 years) undergoing PCI for 404 lesions with 472 DESs (71 patients for 138 lesions with 170 BP-DESs [91 Ultimaster and 79 Synergy] and 163 HD patients for 266 lesions with 302 DP-DESs [219 Xience, 53 Promus and 30 Resolute]) from 2011 to 2017. Two-year clinical outcomes were compared between BP-DES group and DP-DES group. The primary outcome measure was the incidence of target lesion revascularization (TLR), while the secondary outcome measures were the occurrence of cardiac death (CD), stent thrombosis (ST), myocardial infraction (MI), target vessel revascularization (TVR), non-TVR and major adverse cardiac event (MACE) defined as a composite of CD, MI, and TVR. Outcome measures were estimated by the Kaplan-Meier method and the differences between BP-DES group and DP-DES group were assessed by the log-rank test. We also conducted Cox's proportional hazard model to identify predictors for TLR occurrence. Results Baseline patient and lesion characteristics were similar between the two groups. The two-year incidence of TLR was not significantly different between BP-DES group and DP-DES group (14.1% vs. 22.2%, p=0.391). The two-year incidences of CD (17.3% vs. 17.5%, p=0.381), ST (0% vs. 3.9%, p=0.133), MI (4.2% vs. 5.8%, p=0.965), TVR (21.3% vs. 27.5%, p=0.586), non-TVR (26.1% vs. 31.3%, p=0.439) and MACE (41.1% vs. 42.6%, p=0.526) were also not different between the two groups. After multivariate analysis, diabetes mellitus (hazard ratio 1.97; 95% confidence interval 1.03–3.78, p=0.004) was independently associated with TLR occurrence in HD patients. Two-year clinical outcomes of HD patient Conclusions At two-year follow-up after PCI, BP-DES had comparable safety and efficacy profiles to DP-DES in HD patients presenting CAD. Acknowledgement/Funding None

Sign in / Sign up

Export Citation Format

Share Document